^
    2d
    Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy. (PubMed, Clin Cancer Res)
    Sequential VCN-01 plus durvalumab was better tolerated than concomitant treatment. The recommended VCN-01 phase 2 dose (RP2D) was 1.0E13 vp, on the sequential schedule. Encouraging survival was observed in patients after progressing on anti-PD-(L)1 agents. Data supports VCN-01 replication associated with increased PD-1, PD-L1, and CD8 tumor expression. Sequential systemic delivery of VCN-01 and anti-PD-L1 therapy may represent an improved treatment for HNSCC.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • zabilugene almadenorepvec (VCN-01)
    14d
    YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis. (PubMed, Int J Mol Sci)
    Here, we performed an integrative pan-cancer analysis across 53 independent datasets spanning 33 tumour types, incorporating transcriptomic (YBX1 mRNA), proteomic (RPPA), genomic, and clinical data...Elevated YB-1 protein levels were also associated with advanced disease stage and poorer survival outcomes and demonstrated a similar, although non-significant, directional trend with histologic grade. Collectively, these findings demonstrate that elevated YBX1 expression marks proliferative and clinically aggressive tumour states within which genomic instability-related features arise in a context-dependent manner, providing a clarified pan-cancer framework for interpreting YB-1-associated tumour biology.
    Journal • Tumor mutational burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • YBX1 (Y-Box Binding Protein 1)
    |
    HRD
    14d
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Recruiting, Clinica Universidad de Navarra, Universidad de Navarra | Active, not recruiting --> Recruiting
    Enrollment open
    |
    tasadenoturev (DNX-2401)
    26d
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Clinica Universidad de Navarra, Universidad de Navarra | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    tasadenoturev (DNX-2401)
    1m
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra
    Trial initiation date
    |
    tasadenoturev (DNX-2401)
    1m
    PT-112 in Subjects With Thymoma and Thymic Carcinoma (clinicaltrials.gov)
    P2, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Jun 2028
    Trial completion date
    |
    imifoplatin (PT-112)
    1m
    PT-112 in Subjects With Thymoma and Thymic Carcinoma (clinicaltrials.gov)
    P2, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    imifoplatin (PT-112)
    2ms
    A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients with Recurrent Glioblastoma (ChiCTR2600121471)
    P1, N=27, Completed, Huashan Hospital, Shanghai Medical College, Fudan UniversitynBeijing TianTan Hospital,Capital Medical University; Jecho Biopharmaceuticals Co., Ltd
    New P1 trial
    |
    PVR (PVR Cell Adhesion Molecule)
    2ms
    A Single-Arm, Open-Label Phase II Clinical Study to Evaluate the Safety and Efficacy of OVV-01 Injection in Patients with Advanced Soft Tissue Sarcoma (ChiCTR2600120549)
    P=N/A, N=20, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New trial
    2ms
    A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients with Recurrent Glioblastoma (rGBM) (ChiCTR2600119764)
    P1/2, N=90, Huashan Hospital, Shanghai Medical College, Fudan University; nBeijing TianTan Hospital,Capital Medical University; Jecho Biopharmaceuticals Co., Ltd
    New P1/2 trial
    2ms
    ARTACUS: Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (clinicaltrials.gov)
    P1/2, N=69, Active, not recruiting, Replimune, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    2ms
    Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Huashan Hospital
    New P1 trial
    |
    Tecentriq (atezolizumab) • YSCH-01